Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Transitioning an oral therapy into a once-monthly injectable requires launching a completely separate clinical development program. Despite prior oral trials, the FDA requires full Phase 3 studies to independently establish safety and efficacy for the alternate formulation, resetting the regulatory timeline.

Related Insights

Cyclodextrin therapeutics fail to absorb into systemic circulation through the gastrointestinal tract regardless of modifications made to their structure. Consequently, developers must design programs from the outset around subcutaneous injections, self-administered pens, or osmotic pumps rather than attempting oral delivery formulations.

To tackle the high-risk, high-reward obesity market, the company is developing both an injectable and an oral version of the same triple-agonist molecule. The injectable version will enter the clinic first, allowing them to quickly obtain human proof-of-concept and validate the molecule's efficacy before investing heavily in the more complex oral formulation.

The development of SERDs for adjuvant therapy was stalled for two decades not by efficacy concerns, but by logistics. Fulvestrant, the first SERD, required monthly intramuscular injections, a pragmatically unfeasible strategy for a 5-year adjuvant trial, a problem only solved with the advent of oral SERDs.

Pharma teams often fear changing formulations late in development due to perceived regulatory hurdles. However, the path, which involves a relative bioavailability study to bridge the old and new formulations, is a well-established and manageable process if key safety and efficacy metrics are maintained.

For its oral obesity drug Foundeo, Eli Lilly gained approval for a 17mg tablet, despite pivotal trials using a 35mg capsule. The company used a bioequivalence study to justify the switch, a strategic move that halves the amount of active ingredient needed, preemptively addressing massive supply chain challenges.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

The FDA now allows a single, well-designed pivotal trial instead of the traditional two. This reform significantly cuts costs by $100M-$300M and shortens development timelines, enabling companies to test twice as many potential drugs with the same capital.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.

Regulatory bodies like the FDA demand comprehensive characterization for any novel excipient, not just the API. For new delivery vehicles, every new lipid or protein component must be fully understood and proven safe, receiving the same level of scrutiny as the drug substance itself.

Gaining FDA approval for a new delivery system like an on-body injector requires more than showing it works. The Iroclia trial for subcutaneous isatuximab had to meet dual primary endpoints, proving non-inferiority in both clinical efficacy (response rates) and pharmacokinetics (drug levels in the blood), setting a high regulatory bar.